Publications
Journals
Allsopp RC, Guo Q, Page K, et al., 2024, Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study., Breast Cancer Res Treat
Ghorani E, Quartagno M, Blackhall F, et al., 2023, REFINE-Lung implements a novel multi-arm randomisedtrial design to address possible immunotherapy overtreatment, The Lancet Oncology, Vol:24, ISSN:1213-9432, Pages:E219-E227
Coombes RC, Badman PD, Lozano-Kuehne JP, et al., 2023, Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer., Nature Communications, Vol:14, ISSN:2041-1723, Pages:1-1
Conference
Lythgoe M, Dama P, Frampton AE, et al., 2023, Immune modulation and the oral live biotherapeutic product, MRx0518, in treatment-naive patients with cancer: Updated safety data, Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), LIPPINCOTT WILLIAMS & WILKINS, ISSN:0732-183X
Seckl M, Ghorani E, Quartagno M, et al., 2023, REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design, American Society of Clinical Oncology, Pages:TPS9145-TPS9145, ISSN:0732-183X